AssetMark Inc’s Taysha Gene Therapies TSHA Stock Holding History

AssetMark Inc’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8	Closed	-$36	–	3664
2026 Q1	$36	Hold	8	–	–	﹤0.01%	3409
2025 Q4	$44	Buy	+8	New	+$39	﹤0.01%	3341

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AssetMark Inc's TSHA Position: Q2 2026 in Review

AssetMark Inc sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 8 shares — an estimated $36 sold.

AssetMark Inc first reported a position in TSHA in Q4 2025 and held it in 2 quarters. The position peaked at $44 in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

AssetMark Inc reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
AssetMark Inc sold 8 Taysha Gene Therapies shares in Q2 2026, an estimated $36.
AssetMark Inc first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 2 quarters.
AssetMark Inc's Taysha Gene Therapies position peaked at $44 in Q4 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.